EcoDrugPlus

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSFCAG00000002528
Gene Symbol: NR1H3
5 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSFCAG00000006469
Gene Symbol: NR1H4
5 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSFCAG00000026823
Gene Symbol: NR3C1
5 Cross references
280 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSFCAG00000027453
Gene Symbol: NR3C2
5 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSFCAG00000008505
Gene Symbol: NOD2
5 Cross references
167 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSFCAG00000013774
Gene Symbol: OPRK1
5 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSFCAG00000005359
Gene Symbol: OPRM1
5 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSFCAG00000001187
Gene Symbol: OPRL1
5 Cross references
202 Possible Orthologues:

Oxytocin Receptor

Ensembl ID : ENSFCAG00000014726
Gene Symbol: OXTR
5 Cross references
265 Possible Orthologues:

P21 (Rac1) Activated Kinase 4

Ensembl ID : ENSFCAG00000029229
Gene Symbol: PAK4
5 Cross references
160 Possible Orthologues:

Parathyroid Hormone 1 Receptor

Ensembl ID : ENSFCAG00000015473
Gene Symbol: PTH1R
5 Cross references
199 Possible Orthologues:

Peroxisome Proliferator Activated Receptor Alpha

Ensembl ID : ENSFCAG00000005547
Gene Symbol: PPARA
5 Cross references
455 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).